🦋 Making amivantamab + lazertinib safer: new COCOON data at #ESMO26!
New results from the COCOON study suggest that simplified dermatologic prophylaxis, combined with subcutaneous amivantamab + lazertinib, may substantially reduce treatment-related skin toxicity in first-line EGFR-mutant NSCLC. Key findings:Grade ≥2 dermatologic AEs: 39% with standard initiation vs 18% with a one-cycle lazertinib lead-in. Simplified prophylaxis appears to provide protection comparable to the original COCOON regimen. Sc markedly reduces IRR reactions.The new cohorts were non-randomized, and the comparison between initiation strategies was exploratory.
Personal take: No doubt about less ami less tox. Question is if efficacy remains the same in the era of Flaura2?!
#ESMOAmbassador #ESMO26 #LungCancer #NSCLC #EGFR #COCOON #Oncology #CancerResearch
10 views · 1 like · 1 repost · 0 replies
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
https://esmocongress.esmo.orgSource: Alfredo Addeo MD · x.com